Pipeline

Pipeline

NeoImmuneTech, Inc. (NIT) is developing Hyleukin-7 in the clinic, in collaboration with major cancer centers and universities in the US and South Korea, pursuing combination trials with leading immunotherapeutics such as immune checkpoint inhibitors, cancer vaccines and more. NIT pursues clinical development of three key indication areas – cancer, lymphopenia, and HPV-induced diseases.

On top of its previous in vitro and preclinical results, NIT is relentlessly conducting proof-of-concept animal studies in additional indications, such as cancer preventing HPV vaccinations, in order to strengthen our pipeline and broaden the proof of applicability of Hyleukin-7.